FOR IMMEDIATE RELEASE

Aptus Completes First EndoStapling Procedures in Europe

Successful Implants for Aortic Aneurysms Establish Basis for Further Clinical Activity

Sunnyvale, CA, August 6, 2010 — Aptus Endosystems Inc., a medical device company developing advanced
technology for endovascular aneurysm repair (EVAR), announced that several patients with aortic aneurysm disease
have been successfully treated with the Aptus EndoStapling System in Europe. The innovative helical staple technology
enables independent endograft fixation, and is designed to approximate suturing in an open surgical anastomosis. The
company continues to build on its U.S. clinical experience which includes 176 patients and deployment of more than 900
EndoStaples.

Of the procedures performed to date in Europe, the Aptus EndoStapling System was used for secondary interventions to
repair previously implanted endografts as well as in de novo aortic aneurysm patients, where the surgeon(s) believed that
long term patient outcomes would be improved with the addition of radial fixation of the endograft with the EndoStaple.

Jean-Paul P.M. de Vries, M.D., Ph.D., Head of Department of Vascular Surgery, St. Antonius Hospital, Nieuwegein, The
Netherlands performed the first case.

“With the introduction of the Aptus EndoStapling System, proximal fixation of an endograft will be significantly improved,”
said Dr. de Vries. “Its use has a strong potential to decrease the need for post-EVAR follow-up substantially.”

Subsequent Aptus EndoStaple System cases were performed by: Prof. Eric Verhoeven, M.D., Ph.D., Chief of Vascular
and Endovascular Surgery, Klinikum Nürnberg Süd, Nuremberg, Germany; Prof. Ralf Kolvenbach, M.D., Ph.D., Chief of
Vascular Surgery, Augusta Hospital, Dusseldorf, Germany; and Dr. Gaudencio Espinosa, Director of Vascular Surgery,
University of Navarra Hospital, Pamplona, Spain.

“The EndoStapling System performed wonderfully,” said Prof. Verhoeven. “In unfriendly anatomy, I was able to staple a
proximal cuff to repair a Type I endoleak of an endograft that had tilted.”

“Completing our first cases in Europe marks a significant milestone for Aptus Endosystems,” commented Jeff Elkins, CEO
of Aptus Endosystems, Inc. “This initial commercial experience supports the success that we saw with our EndoStapling
System in the U.S. The novel concept of independent and physician controlled proximal fixation using the EndoStapling
System is a considerable step toward preventing long term complications and making EVAR the definitive solution in
treating aortic aneurysms.”

About Aptus Endosystems, Inc.

Aptus Endosystems is a privately held medical technology company that has developed advanced technology for the
endovascular treatment of aortic aneurysm disease. Founded in 2002, Aptus Endosystems has developed a unique
endograft and endovascular stapling system delivered via standard catheter technology. The technology allows
surgeons to treat abdominal aortic aneurysms through a minimally invasive approach while still providing the control of an
open repair. The Aptus Endovascular AAA Repair Systems bear the CE Marking for distribution in the European Union.
These products are Investigational Use only in the United States. For more information, please
visit www.aptusendosystems.com

###
Media Contact:
Aptus Endosystems, Inc.
Jeff Elkins
CEO
Ph: 408.530.9050
jelkins@aptusendo.com